Genus PLC Market Cap ($19.33 Million)
Market Cap & Net Worth: Genus PLC (GNS)
Genus PLC market cap. Genus PLC (LSE:GNS) has a market capitalization of $19.33 Million (GBX158.86 Billion) as of November 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #25053 globally and #261 in its home market, demonstrating a 4.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genus PLC's stock price GBX2392.00 by its total outstanding shares 66412699 (66.41 Million). Also see GNS cash flow conversion for how efficiently the company converts equity into cash flow.
Genus PLC Market Cap History (2015–2026)
Genus PLC market cap history from 2015 to 2026. Data shows growth from $11.37 Million to $19.33 Million (5.56% CAGR). Check Genus PLC share price for real-time trading data and today's change.
Index Memberships
Genus PLC is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$67.98 Billion | 0.03% | #186 of 573 |
|
FTSE 350
FTLC
|
$67.91 Billion | 0.03% | #184 of 350 |
|
FTSE 250
FTMC
|
$9.51 Billion | 0.20% | #93 of 250 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$3.63 Billion | 0.53% | #4 of 6 |
Weight: Genus PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genus PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genus PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GNS net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.03x
Genus PLC's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.09x
Genus PLC's market cap is 1.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $13.30 Million | $388.30 Million | $49.30 Million | 0.03x | 0.27x |
| 2017 | $18.96 Million | $459.10 Million | $32.80 Million | 0.04x | 0.58x |
| 2018 | $16.27 Million | $470.30 Million | $42.70 Million | 0.03x | 0.38x |
| 2019 | $24.32 Million | $488.50 Million | $7.80 Million | 0.05x | 3.12x |
| 2020 | $32.36 Million | $551.40 Million | $35.30 Million | 0.06x | 0.92x |
| 2021 | $38.31 Million | $574.30 Million | $47.30 Million | 0.07x | 0.81x |
| 2022 | $23.39 Million | $593.40 Million | $40.90 Million | 0.04x | 0.57x |
| 2023 | $17.24 Million | $689.70 Million | $33.30 Million | 0.03x | 0.52x |
| 2024 | $12.52 Million | $668.80 Million | $7.90 Million | 0.02x | 1.59x |
| 2025 | $20.97 Million | $672.80 Million | $19.30 Million | 0.03x | 1.09x |
Competitor Companies of GNS by Market Capitalization
Companies near Genus PLC in the global market cap rankings as of November 7, 2026. Also see GNS current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Genus PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Genus PLC (2015–2026)
Market capitalization of Genus PLC from 2015 to today. Between 2015 and today, Genus PLC's market cap moved from $11.37 Million to $ 19.33 Million, with a yearly change of 5.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX19.33 Million | -7.82% |
| 2025 | GBX20.97 Million | +67.42% |
| 2024 | GBX12.52 Million | -27.36% |
| 2023 | GBX17.24 Million | -26.28% |
| 2022 | GBX23.39 Million | -38.95% |
| 2021 | GBX38.31 Million | +18.39% |
| 2020 | GBX32.36 Million | +33.08% |
| 2019 | GBX24.32 Million | +49.48% |
| 2018 | GBX16.27 Million | -14.20% |
| 2017 | GBX18.96 Million | +42.56% |
| 2016 | GBX13.30 Million | +16.99% |
| 2015 | GBX11.37 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Genus PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.33 Million USD |
| MoneyControl | $19.33 Million USD |
| MarketWatch | $19.33 Million USD |
| marketcap.company | $19.33 Million USD |
| Reuters | $19.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genus PLC
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as techni… Read more